175 related articles for article (PubMed ID: 20008549)
1. A strategy for risk management of drug-induced phospholipidosis.
Chatman LA; Morton D; Johnson TO; Anway SD
Toxicol Pathol; 2009 Dec; 37(7):997-1005. PubMed ID: 20008549
[TBL] [Abstract][Full Text] [Related]
2. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
3. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
[TBL] [Abstract][Full Text] [Related]
4. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase.
Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V
Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623
[TBL] [Abstract][Full Text] [Related]
5. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
6. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential.
Kasahara T; Tomita K; Murano H; Harada T; Tsubakimoto K; Ogihara T; Ohnishi S; Kakinuma C
Toxicol Sci; 2006 Mar; 90(1):133-41. PubMed ID: 16338956
[TBL] [Abstract][Full Text] [Related]
7. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.
Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J
Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096
[TBL] [Abstract][Full Text] [Related]
8. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach.
Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P
Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced phospholipidosis.
Anderson N; Borlak J
FEBS Lett; 2006 Oct; 580(23):5533-40. PubMed ID: 16979167
[TBL] [Abstract][Full Text] [Related]
10. Predicting the Risk of Phospholipidosis with in Silico Models and an Image-Based in Vitro Screen.
Fusani L; Brown M; Chen H; Ahlberg E; Noeske T
Mol Pharm; 2017 Dec; 14(12):4346-4352. PubMed ID: 29077420
[TBL] [Abstract][Full Text] [Related]
11. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities.
Tengstrand EA; Miwa GT; Hsieh FY
Expert Opin Drug Metab Toxicol; 2010 May; 6(5):555-70. PubMed ID: 20370598
[TBL] [Abstract][Full Text] [Related]
12. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
Sawada H; Takami K; Asahi S
Toxicol Sci; 2005 Feb; 83(2):282-92. PubMed ID: 15342952
[TBL] [Abstract][Full Text] [Related]
13. Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone.
Natale A; Boeckmans J; Desmae T; De Boe V; De Kock J; Vanhaecke T; Rogiers V; Rodrigues RM
Toxicol Lett; 2018 Mar; 284():184-194. PubMed ID: 29248575
[TBL] [Abstract][Full Text] [Related]
14. Cellular responses associated with dibucaine-induced phospholipidosis.
Peropadre A; Fernández Freire P; Herrero O; Pérez Martín JM; Hazen MJ
Chem Res Toxicol; 2011 Feb; 24(2):185-92. PubMed ID: 21261262
[TBL] [Abstract][Full Text] [Related]
15. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
16. Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk.
Wang T; Feng Y; Jin X; Fan X; Crommen J; Jiang Z
J Pharm Biomed Anal; 2014 Aug; 96():263-71. PubMed ID: 24814828
[TBL] [Abstract][Full Text] [Related]
17. Validation of an in vitro screen for phospholipidosis using a high-content biology platform.
Morelli JK; Buehrle M; Pognan F; Barone LR; Fieles W; Ciaccio PJ
Cell Biol Toxicol; 2006 Jan; 22(1):15-27. PubMed ID: 16463016
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages.
McCloud CM; Beard TL; Kacew S; Reasor MJ
Exp Mol Pathol; 1995 Feb; 62(1):12-21. PubMed ID: 7556587
[TBL] [Abstract][Full Text] [Related]
19. Urinary metabolic fingerprinting for amiodarone-induced phospholipidosis in rats using FT-ICR MS.
Hasegawa M; Takenaka S; Kuwamura M; Yamate J; Tsuyama S
Exp Toxicol Pathol; 2007 Oct; 59(2):115-20. PubMed ID: 17719757
[TBL] [Abstract][Full Text] [Related]
20. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]